<DOC>
	<DOCNO>NCT00009880</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Combining chemotherapy radiation therapy may kill tumor cell . PURPOSE : Randomized phase II trial compare effectiveness combination chemotherapy plus radiation therapy without fluorouracil treat patient cancer esophagus stomach .</brief_summary>
	<brief_title>Combination Chemotherapy Plus Radiation Therapy With Without Fluorouracil Treating Patients With Cancer Esophagus Stomach</brief_title>
	<detailed_description>OBJECTIVES : - Compare survival failure pattern patient previously untreated carcinoma esophagus gastroesophageal junction treat cisplatin , paclitaxel , concurrent radiotherapy without fluorouracil . - Compare tolerance regimens patient . - Compare overall quality life patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify accord percentage weight loss ( le 10 % vs 10 % ) , disease histology ( adenocarcinoma vs squamous cell carcinoma ) , lesion size ( 5 cm v 5 cm ) . Patients randomize one two treatment arm . - Arm I : Patients receive induction chemotherapy comprise fluorouracil IV continuously 24 hour cisplatin IV 1 hour day 1-5 , paclitaxel IV continuously 24 hour day 1 , filgrastim ( G-CSF ) subcutaneously daily day 6-15 . Treatment repeat every 4 week 2 course . Patients stable responsive disease first course induction therapy receive second course therapy . Patients local disease progression first course proceed chemoradiotherapy . Beginning day 29 last course induction chemotherapy , patient undergo radiotherapy 5 day week 5.5 week . Patients also receive fluorouracil IV continuously 24 hour day 1-5 , 8-12 , 15-19 , 22-26 , 29-33 , paclitaxel IV 3 hour day 1 , 8 , 15 , 22 , 29 . - Arm II : Patients receive induction chemotherapy comprise cisplatin IV paclitaxel IV 3 hour day 1 . Treatment continue every 3 week 2 course arm I . Beginning day 29 last course induction chemotherapy , patient undergo radiotherapy arm I . Patients also receive cisplatin IV day 1 , 8 , 15 , 22 , 29 , 36 , paclitaxel IV continuously 96 hour day 1-4 , 8-11 , 15-18 , 22-25 , 29-32 , 36-39 . Quality life assess baseline , within 1 week radiotherapy , 6 week study completion , every 4 month 1 year , every 6 month 2 year , annually 5 year . Patients follow within 8 week , every 4 month 1 year , every 6 month two year , annually thereafter . PROJECTED ACCRUAL : A total 84 patient ( 42 per treatment arm ) accrue study within 21 month .</detailed_description>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm primary squamous cell carcinoma adenocarcinoma esophagus gastroesophageal junction Stage IIII ( T1 , N1 , M0 ; T24 , N , M0 ) Supraclavicular celiac lymph node involvement allow Disease entirely confine esophagus gastroesophageal junction periesophageal soft tissue Cervical esophageal carcinoma allow No tumor extension beyond 2 cm stomach No multiple primary carcinoma esophagus No evidence disseminate cancer No tracheoesophageal fistula direct invasion mucosa trachea major bronchus Bronchoscopy biopsy cytology require primary carcinoma le 26 cm incisor carina image study PATIENT CHARACTERISTICS : Age : Not specify Performance status : Zubrod 01 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 150,000/mm^3 Hemoglobin least 10 g/dL Hepatic : Not specify Renal : Creatinine great 1.5 mg/dL Creatinine clearance least 65 mL/min Cardiovascular : No uncontrolled heart disease No uncontrolled hypertension Other : Total oral/enteral intake must least 1,700 kCal/day Not pregnant nursing Fertile patient must use effective contraception No uncontrolled diabetes No malignancy within past 5 year except curatively treat nonmelanoma skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior systemic chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior chest radiotherapy Surgery : No prior major esophageal surgery</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2004</verification_date>
	<keyword>stage I gastric cancer</keyword>
	<keyword>stage II gastric cancer</keyword>
	<keyword>stage III gastric cancer</keyword>
	<keyword>stage I esophageal cancer</keyword>
	<keyword>stage II esophageal cancer</keyword>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>adenocarcinoma stomach</keyword>
	<keyword>squamous cell carcinoma esophagus</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
</DOC>